US Edition
NICE recommends Benralizumab for Rare Form of Vasculitis - Pharmafile
Summary by pharmafile.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
NICE recommends Benralizumab for Rare Form of Vasculitis - Pharmafile
The National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca’s benralizumab (Fasenra) as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA). This marks the first NHS-funded biologic treatment option for eligible patients in England, with interim funding allowing immediate access. The recommendation is based on results […] The post NICE recommends Be…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
